Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Formula of medicament for treating non-infectious ocular inflammations, and inhibiting corneal neovascularization and anti-rejection reaction generated after corneal grafting

A corneal neovascularization, non-infectious technology, applied in pharmaceutical formulations, medical preparations with inactive ingredients, and medical preparations containing active ingredients, etc., can solve the problems of easy inactivation, reduced dosage, and high external environment requirements. To achieve the effect of easy preservation, improved activity and good therapeutic effect

Inactive Publication Date: 2011-10-12
BEIJING DAZHOU HEKANG BIO TECH
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] In order to overcome the problem that recombinant human interleukin-1 receptor antagonists have high requirements on the external environment and are easy to inactivate in the prior art, and by adding recombinant human interleukin-8 receptor antagonists and chemokine-like factors 1 produces a synergistic effect with recombinant human interleukin-1 receptor antagonists to reduce the dosage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Formula of medicament for treating non-infectious ocular inflammations, and inhibiting corneal neovascularization and anti-rejection reaction generated after corneal grafting
  • Formula of medicament for treating non-infectious ocular inflammations, and inhibiting corneal neovascularization and anti-rejection reaction generated after corneal grafting
  • Formula of medicament for treating non-infectious ocular inflammations, and inhibiting corneal neovascularization and anti-rejection reaction generated after corneal grafting

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Embodiment 1 chooses that isotonic agent is glycerin and isotonic agent is the test result comparison of mannitol

[0031] Formula 1 (the existing formula used): 40 g of disodium hydrogen phosphate (buffer), 20 g of potassium dihydrogen phosphate (buffer), 30 g of potassium chloride (buffer), 70 g of mannitol, 2 g of human serum albumin, Recombinant human interleukin-1 receptor antagonist 50mg is prepared into 1000ml solution with sterile water.

[0032] Formula 2 Glycerin replaces mannitol, and the weight of glycerin is 10g.

[0033] Formula 3 Glycerin replaces mannitol, and the weight of glycerin is 20g.

[0034] Formula 4 Glycerin replaces mannitol, and the weight of glycerin is 30g.

[0035] Formula 5 glycerin replaces mannitol, and the weight of glycerin is 40g.

[0036] Choose every kind of formula solution to pack into 50 bottles, each bottle is 10 milliliters, and the test results are averaged.

[0037]

[0038] As can be seen from the results in Table 1,...

Embodiment 2

[0039] Embodiment 2 adopts the test result of sodium citrate and citric acid combination and disodium hydrogen phosphate and potassium dihydrogen phosphate contrast

[0040] Table 2 Comparison of different test results of buffer

[0041]

[0042] Formula 1 (the existing formula used): 40 g of disodium hydrogen phosphate (buffer), 20 g of potassium dihydrogen phosphate (buffer), 30 g of potassium chloride (buffer), 70 g of mannitol, 2 g of human serum albumin, Recombinant human interleukin-1 receptor antagonist 50mg is prepared into 1000ml solution with sterile water.

[0043] Formula 2 uses a combination of sodium citrate and citric acid as a buffer to replace the combination of disodium hydrogen phosphate and potassium dihydrogen phosphate, and the sodium citrate and citric acid are 40g and 20g respectively.

[0044] Formula 3 uses a combination of sodium citrate and citric acid as a buffer to replace the combination of disodium hydrogen phosphate and potassium dihydrogen...

Embodiment 3

[0047] Embodiment 3 adds preservative comparative test

[0048] Table 3 Adding preservatives and comparing the experimental results without adding

[0049]

[0050] Formula 1 (the existing formula used): 40 g of disodium hydrogen phosphate (buffer), 20 g of potassium dihydrogen phosphate (buffer), 30 g of potassium chloride (buffer), 70 g of mannitol, 2 g of human serum albumin, Recombinant human interleukin-1 receptor antagonist 50mg is prepared into 1000ml solution with sterile water.

[0051] Formula 2 adds 0.2 g of ethyl p-hydroxybenzoate on the basis of formula 1.

[0052] Choose every kind of formula, and solution is packed into 50 bottles, and every bottle is 50 milliliters, and test result is averaged.

[0053] From the test results in Table 3, it can be known that adding a preservative can better keep the recombinant human interleukin-1 receptor antagonist in a sterile and qualified state, and keep its activity stable for a longer period of time.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a formula of a medicament for treating non-infectious ocular inflammations, and inhibiting the corneal neovascularization and the anti-rejection reaction generated after corneal grafting. Through the selection of an isotonizing agent and a buffering agent and the addition of an antiseptic agent, a release microsphere preparation, a recombinant human interleukin-8 receptor antagonist and a chemokine-like factors 1 (CKLF1), the activity of a recombinant human interleukin-1 receptor antagonist is enhanced, and the retention time thereof is extended. In the invention, the problem that in the prior art, because of having a high environmental requirement on the outside, the existing recombinant human interleukin-1 receptor antagonist is easy to inactivate is solved; and through adding the recombinant human interleukin-8 receptor antagonist and the chemokine-like factors 1 (CKLF1) into the medicament, a synergistic effect is generated among the recombinant human interleukin-8 receptor antagonist, the chemokine-like factors 1 (CKLF1) and the recombinant human interleukin-1 receptor antagonist, thereby reducing the dosage of the medicament.

Description

technical field [0001] The invention relates to a formula for treating eye diseases, especially a formula for treating non-infectious eye inflammation, inhibiting corneal neovascularization and resisting rejection after corneal transplantation. Background technique [0002] IL-1 plays a key role in initiating the inflammatory response of the body. IL-1 is involved in the occurrence and development of many human diseases. IL-1 itself can not only attract inflammatory response cells in the body to the site of inflammation, but also stimulate the production of various inflammatory mediators in the body. This further intensifies the inflammatory response. Therefore, how to eliminate the influence of IL-1 will play an important role in curing some inflammatory diseases. IL-1ra is an IL-1 antagonist that occurs naturally in the body. It can specifically bind to the IL-1 receptor on the cell surface without activating the target cells, thereby blocking the biological activity of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K38/17A61K38/19A61K9/16A61K47/48A61P27/02
Inventor 宋东光
Owner BEIJING DAZHOU HEKANG BIO TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com